[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2002019995A2 - Pharmaceutical combination containing salmeterol and fluticasone - Google Patents

Pharmaceutical combination containing salmeterol and fluticasone Download PDF

Info

Publication number
WO2002019995A2
WO2002019995A2 PCT/GB2001/004001 GB0104001W WO0219995A2 WO 2002019995 A2 WO2002019995 A2 WO 2002019995A2 GB 0104001 W GB0104001 W GB 0104001W WO 0219995 A2 WO0219995 A2 WO 0219995A2
Authority
WO
WIPO (PCT)
Prior art keywords
salmeterol
fluticasone propionate
rhinitis
physiologically acceptable
acceptable salt
Prior art date
Application number
PCT/GB2001/004001
Other languages
French (fr)
Other versions
WO2002019995A3 (en
Inventor
Smithkline Glaxo
Original Assignee
Glaxo Group Limited
Smithkline Glaxo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited, Smithkline Glaxo filed Critical Glaxo Group Limited
Priority to AU2001284287A priority Critical patent/AU2001284287A1/en
Publication of WO2002019995A2 publication Critical patent/WO2002019995A2/en
Publication of WO2002019995A3 publication Critical patent/WO2002019995A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Definitions

  • the present invention relates to the use of salmeterol and fluticasone propionate combinations for the treatment of rhinitis.
  • beta-2 adrenergic agonist salmeterol or a physiologically acceptable salt thereof has been described in GB 2 235 627 for use in the treatment of asthma and other respiratory disorders.
  • Fluticasone propionate is itself known from GB 2 088 877 to have anu- inflammatory activity and to be useful for the treatment of allergic and inflammatory conditions of the nose, throat, or lungs such as asthma and rhinitis, including hay fever.
  • Salmeterol is known from GB 2 140 800 and is used clinically in the form of its xinafoate salt for the treatment of asthma. There is no precedent for the use of a beta-2 adrenergic agonist, in particular salmeterol in combination with a corticosteroid as an effective therapy for rhinitis.
  • Rhinitis is characterised by a combination of sneezing, nasal discharge and blockage lasting at least ah hour on most days.
  • rhinitis includes allergic rhinitis which may be seasonal as in hay fever, or perennial, and non-allergic rhinitis.
  • the present invention also relates to the treatment of sinusitis.
  • rhinitis also includes sinusitis whether present as a complication of rhinitis or not.
  • the present invention relates to treatment of allergic rhinitis, meaning rhinitis caused by an allergen to which the patient is exposed such as pollen, dust, danders, food, and mould.
  • Allergic rhinitis is characterised by sudden attacks of sneezing, swelling of the nasal mucosa with watery discharge, itching of the eyes and lacrimation.
  • the present invention provides a method for prophylaxis or treatment of rhinitis in a mammal, such as a human, which comprises administering an effective amount of a combination of salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate.
  • a method for prophylaxis or treatment of allergic rhinitis in a mammal, such as a human which comprises administering an effective amount of a combination " of salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate.
  • a combination of salmeterol or a physiologically acceptable salt thereof such as the xinafoate salt, and fluticasone propionate for the manufacture of a medicament for the prophylaxis or treatment of rhinitis.
  • a combination of salmeterol or a physiologically acceptable salt thereof such as the xinafoate salt, and fluticasone propionate for the manufacture of a medicament for prophylaxis or treatment of allergi ⁇ rhinitis.
  • treatment means the improvement of clinical outcome, for example, alleviation of the symptoms of rhinitis, in particular reduction of sneezing, itching nose, runny nose, nasal blockage, and/or itching eyes.
  • treatment of rhinitis includes a reduction of complications such as sinusitis and otitis media.
  • the compounds of the salmeterol and fluticasone propionate combination may be administered simultaneously, either in the same or different pharmaceutical formulations, or sequentially. Where there is sequential administration, the delay in administering the second and any subsequent active ingredient should not be such as to lose the beneficial therapeutic effect of the combination of the active ingredients.
  • the salmeterol or its physiologically acceptable salt and the fluticasone propionate are administered as a combined pharmaceutical formulation.
  • the weight/weight ratio of salmeterol to fluticasone administered according to the invention is preferably in the range 4:1 to 1 :20.
  • the amount of salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate which is required to achieve a therapeutic effect will, of course, vary with the particular salt form, the route of administration, the subject under treatment, and the particular disorder or disease being treated.
  • the combination of the invention may be administered intranasally to an adult human at a dose of from 50 ⁇ g to 2000 ⁇ g per day, suitably 50 ⁇ g to 500 ⁇ g per day, more suitably 100 ⁇ g to 400 ⁇ g per day of fluticasone propionate and 50 ⁇ g to 200 ⁇ g per day, suitably 50 ⁇ g to 10O ⁇ g per day of salmeterol.
  • the daily dose may be administered as several sub-doses, for example, twice daily, but will preferably be administered once daily
  • salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate it is preferable to present each of them as a pharmaceutical formulation.
  • a pharmaceutical formulation for the prophylaxis or treatment of rhinitis comprising salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic agents.
  • the pharmaceutical formulation is in a form which is suitable for intranasal administration.
  • active ingredient means salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and/or fluticasone propionate.
  • Suitable formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), inhalation (including fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers or insufflators), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • the pharmaceutical formulations used in accordance with the present invention are suitable for intranasal administration.
  • Intranasal formulations may be in the form of powder compositions which will preferably contain lactose, or spray compositions which may be formulated, for example, as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetra-fluoroethane, 1 ,1 ,1 ,2,3,3,3-heptafluoro- propane, 1 ,1 ,1 ,2-tetrafluoroethane, carbon dioxide or other suitable gas.
  • Suitable aerosol spray compositions for use in accordance with the invention are described in WO 93/11743.
  • Intranasal sprays may be formulated with aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants.
  • agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants.
  • Capsules and cartridges of for example gelatin, or blisters of for example laminated aluminium foil, for use in an inhaler or insuflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • Solutions for inhalation by nebulisation may be formulated with an aqueous vehicle with the addition of agents such as acid or alkali, buffer salts, isotonicity adjusting agents or antimicrobials. They may be sterilised by filtration or heating in an autoclave, or presented as a non-sterile product.
  • the formulations used according to the invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
  • the combination of salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate used according to the present invention may be used in combination with a further active ingredient, for example an antihistamine such as terfenidine, astemizole, cetirizine, loratidine, chlorpheniramine, clemastine, hydroxyzine, cyproheptadine, ketotifen, levocabastinem or azelastine, a decongestant such as ephidrine, pseudoephidrine, or phenylpropanolamine, an anticholinergic such as ipratropium, tiotropium or oxitropium, another anti- inflammatory agent such as cromogly
  • Example 1 25/50 salmeterol/fluticasone propionate metered dose inhaler
  • micronised active ingredients are weighed into an aluminium can, 1 ,1 ,1 ,2- tetrafluoroethane is then added from a vacuum flask and a metering valve is crimped into place.
  • Example 2 25/125 salmeterol/fluticasone propionate metered dose inhaler
  • a randomised , placebo-controlled, double-blind, cross-over study was conducted which compared the effects of the nasal fluticasone propionate (FP, data not shown), fluticasone propionate and salmeterol combination (FSC) and placebo, on nasal clinical symptoms and nasal blockage following intranasal allergen challenge.
  • the study was conducted in 47 subjects with a history of allergic rhinitis to grass pollen, outside the grass pollen season. Subjects were treated for 7 days with either FP (200mcg/day), FSC (200/1 OOmcg/day; FP/salmete ' rol) or placebo, delivered via a metered-dose inhaler (MDI) with a nasal actuator. On Day 7, subjects were challenged with timothy grass pollen extract.
  • MDI metered-dose inhaler
  • CAT categorical nasal symptom score
  • VAS visual analogue score
  • PNIF peak inspiratory nasal flow
  • Nasal symptoms and PNIF were recorded at intervals over a 10.5h period post challenge and the mean total symptom score determined.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of salmeterol and fluticasone propionate combinations for the prophylaxis and treatment of rhinitis.

Description

Use of pharmaceutical combination
The present invention relates to the use of salmeterol and fluticasone propionate combinations for the treatment of rhinitis.
The combination of the beta-2 adrenergic agonist salmeterol or a physiologically acceptable salt thereof and the corticosteroid fluticasone propionate has been described in GB 2 235 627 for use in the treatment of asthma and other respiratory disorders.
Fluticasone propionate is itself known from GB 2 088 877 to have anu- inflammatory activity and to be useful for the treatment of allergic and inflammatory conditions of the nose, throat, or lungs such as asthma and rhinitis, including hay fever.
Salmeterol is known from GB 2 140 800 and is used clinically in the form of its xinafoate salt for the treatment of asthma. There is no precedent for the use of a beta-2 adrenergic agonist, in particular salmeterol in combination with a corticosteroid as an effective therapy for rhinitis.
Rhinitis is characterised by a combination of sneezing, nasal discharge and blockage lasting at least ah hour on most days. As used herein, the term "rhinitis" includes allergic rhinitis which may be seasonal as in hay fever, or perennial, and non-allergic rhinitis.
The present invention also relates to the treatment of sinusitis. As used herein the term "rhinitis" also includes sinusitis whether present as a complication of rhinitis or not. In a more particular aspect, the present invention relates to treatment of allergic rhinitis, meaning rhinitis caused by an allergen to which the patient is exposed such as pollen, dust, danders, food, and mould. Allergic rhinitis is characterised by sudden attacks of sneezing, swelling of the nasal mucosa with watery discharge, itching of the eyes and lacrimation.
We now propose that the use of a combination of salmeterol or a physiologically acceptable salt thereof and fluticasone propionate may have clinical advantages in the treatment of rhinitis over the use of fluticasone propionate alone.
Accordingly, the present invention provides a method for prophylaxis or treatment of rhinitis in a mammal, such as a human, which comprises administering an effective amount of a combination of salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate. In particular, there is provided a method for prophylaxis or treatment of allergic rhinitis in a mammal, such as a human, which comprises administering an effective amount of a combination" of salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate.
In the alternative, there is provided the use of a combination of salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate for the manufacture of a medicament for the prophylaxis or treatment of rhinitis. In particular, there is provided the use of a combination of salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate for the manufacture of a medicament for prophylaxis or treatment of allergiς rhinitis. As used herein, the term "treatment" means the improvement of clinical outcome, for example, alleviation of the symptoms of rhinitis, in particular reduction of sneezing, itching nose, runny nose, nasal blockage, and/or itching eyes.
In a further aspect of the invention, treatment of rhinitis includes a reduction of complications such as sinusitis and otitis media.
Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and
'comprising', will be understood to imply the inclusion of a stated integer or step or group of integers but not to the exclusion of any other integer or step or group of integers or steps.
It will be appreciated that the compounds of the salmeterol and fluticasone propionate combination may be administered simultaneously, either in the same or different pharmaceutical formulations, or sequentially. Where there is sequential administration, the delay in administering the second and any subsequent active ingredient should not be such as to lose the beneficial therapeutic effect of the combination of the active ingredients. In a preferred aspect of the invention, the salmeterol or its physiologically acceptable salt and the fluticasone propionate are administered as a combined pharmaceutical formulation. The weight/weight ratio of salmeterol to fluticasone administered according to the invention is preferably in the range 4:1 to 1 :20.
The amount of salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate which is required to achieve a therapeutic effect will, of course, vary with the particular salt form, the route of administration, the subject under treatment, and the particular disorder or disease being treated. The combination of the invention may be administered intranasally to an adult human at a dose of from 50μg to 2000μg per day, suitably 50μg to 500μg per day, more suitably 100μg to 400μg per day of fluticasone propionate and 50μg to 200μg per day, suitably 50μg to 10Oμg per day of salmeterol. The daily dose may be administered as several sub-doses, for example, twice daily, but will preferably be administered once daily
While it is possible for salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate to be administered as raw drugs, it is preferable to present each of them as a pharmaceutical formulation.
Thus according to a further aspect of the invention, there is provided a pharmaceutical formulation for the prophylaxis or treatment of rhinitis comprising salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic agents. Preferably, the pharmaceutical formulation is in a form which is suitable for intranasal administration.
Hereinafter, the term "active ingredient" means salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and/or fluticasone propionate.
Suitable formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), inhalation (including fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers or insufflators), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
Preferably, the pharmaceutical formulations used in accordance with the present invention are suitable for intranasal administration. Intranasal formulations may be in the form of powder compositions which will preferably contain lactose, or spray compositions which may be formulated, for example, as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetra-fluoroethane, 1 ,1 ,1 ,2,3,3,3-heptafluoro- propane, 1 ,1 ,1 ,2-tetrafluoroethane, carbon dioxide or other suitable gas. Suitable aerosol spray compositions for use in accordance with the invention are described in WO 93/11743.
Intranasal sprays may be formulated with aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants.
Capsules and cartridges of for example gelatin, or blisters of for example laminated aluminium foil, for use in an inhaler or insuflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch. Solutions for inhalation by nebulisation may be formulated with an aqueous vehicle with the addition of agents such as acid or alkali, buffer salts, isotonicity adjusting agents or antimicrobials. They may be sterilised by filtration or heating in an autoclave, or presented as a non-sterile product.
It should be Understood that in addition to the ingredients particularly mentioned above, the formulations used according to the invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents. Furthermore, the combination of salmeterol or a physiologically acceptable salt thereof, such as the xinafoate salt, and fluticasone propionate used according to the present invention may be used in combination with a further active ingredient, for example an antihistamine such as terfenidine, astemizole, cetirizine, loratidine, chlorpheniramine, clemastine, hydroxyzine, cyproheptadine, ketotifen, levocabastinem or azelastine, a decongestant such as ephidrine, pseudoephidrine, or phenylpropanolamine, an anticholinergic such as ipratropium, tiotropium or oxitropium, another anti- inflammatory agent such as cromoglycate, a leukotriene receptor antagonist, 5- lipoxygenase inhibitor or an inhibitor of phophodiesterase III and/or IV.
EXAMPLES
Example 1 : 25/50 salmeterol/fluticasone propionate metered dose inhaler
Figure imgf000007_0001
The micronised active ingredients are weighed into an aluminium can, 1 ,1 ,1 ,2- tetrafluoroethane is then added from a vacuum flask and a metering valve is crimped into place.
Similar methods may be used for the formulation of Example 2:
Example 2: 25/125 salmeterol/fluticasone propionate metered dose inhaler
Figure imgf000008_0001
Example 3
A randomised , placebo-controlled, double-blind, cross-over study was conducted which compared the effects of the nasal fluticasone propionate (FP, data not shown), fluticasone propionate and salmeterol combination (FSC) and placebo, on nasal clinical symptoms and nasal blockage following intranasal allergen challenge. The study was conducted in 47 subjects with a history of allergic rhinitis to grass pollen, outside the grass pollen season. Subjects were treated for 7 days with either FP (200mcg/day), FSC (200/1 OOmcg/day; FP/salmete'rol) or placebo, delivered via a metered-dose inhaler (MDI) with a nasal actuator. On Day 7, subjects were challenged with timothy grass pollen extract.
Subject rated nasal symptoms of nasal blockage, rhinorrhoea and sneezing were recorded pre and post challenge using a categorical nasal symptom score (CAT) and a visual analogue score (VAS). The CAT score was measured on a 5 point scale as follows:
Figure imgf000009_0001
For the VAS, subjects were asked to rate the extent of each symptom by placing a vertical mark on a horizontal 10cm line with the left-hand end defined as "no symptoms" and the right-hand end defined as "worst ever symptoms". In addition, peak inspiratory nasal flow (PNIF) was measured pre and post challenge as a measure of nasal obstruction.
Nasal symptoms and PNIF were recorded at intervals over a 10.5h period post challenge and the mean total symptom score determined.
Nasal FSC reduced mean total nasal symptom scores and this was significant as determined by CAT score (Table 1). Consistent with this reduction in nasal clinical symptoms, FSC significantly increased PNIF indicating a reduction in nasal obstruction (Figure 1 ; Table 1). Figure 1 shows the mean PNIF on day 7. Ratio 95% Cl
Categorical FSC/Placebo 0.86 0.75, 0.99
VAS FSC/Placebo 0.86 0.71 , 1.05
PNIF FSC/Placebo 1.12 1.06, 1.19
(L/min)

Claims

ΘCLAIMS
1. A method for prophylaxis or treatment of rhinitis in a mammal, such as a human, which comprises administering an effective amount of a combination 5 of salmeterol or a physiologically acceptable salt thereof and fluticasone propionate.
2. A method according to claim 1 wherein the salmeterol or physiologically acceptable salt thereof and fluticasone propionate are administered as a 0 combined pharmaceutical formulation.
3. A method according to claim 1 or claim 2 in which the salmeterol or physiologically acceptable salt thereof and fluticasone propionate are administered intranasally.
4. A method according to any one of claims 1 to 3 in which the salmeterol is administered as the xinafoate salt.
5. Use of a combination of salmeterol or a physiologically acceptable salt thereof and fluticasone propionate for the manufacture of a medicament for the prophylaxis or treatment of rhinitis.
6. Use according to claim 5 wherein the medicament is a combined pharmaceutical formulation.
7. Use according to claim 5 or claim 6 in which the medicament is suitable for intranasal administration.
8. Use. according to any one of claims 5 to 7 in which the salmeterol is in the form of the xinafoate salt.
9. A pharmaceutical formulation for the prophylaxis or treatment of rhinitis comprising salmeterol or a physiologically acceptable salt thereof and fluticasone propionate, and a pharmaceutically acceptable carrier or excipient and optionally one or more other therapeutic agents.
10. A pharmaceutical formulation according to claim 9 which is in a form suitable for intranasal administration.
11. A pharmaceutical formulation according to claim 9 or claim 10 in which the . salmeterol is in the form of the xinafoate salt.
PCT/GB2001/004001 2000-09-07 2001-09-06 Pharmaceutical combination containing salmeterol and fluticasone WO2002019995A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001284287A AU2001284287A1 (en) 2000-09-07 2001-09-06 Pharmaceutical combination containing salmeterol and fluticasone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021927.9A GB0021927D0 (en) 2000-09-07 2000-09-07 Use of pharmaceutical combination
GB0021927.9 2000-09-07

Publications (2)

Publication Number Publication Date
WO2002019995A2 true WO2002019995A2 (en) 2002-03-14
WO2002019995A3 WO2002019995A3 (en) 2002-08-22

Family

ID=9899002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004001 WO2002019995A2 (en) 2000-09-07 2001-09-06 Pharmaceutical combination containing salmeterol and fluticasone

Country Status (3)

Country Link
AU (1) AU2001284287A1 (en)
GB (1) GB0021927D0 (en)
WO (1) WO2002019995A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033000A1 (en) * 2001-10-12 2003-04-24 Glaxo Group Limited Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03178929A (en) * 1989-09-07 1991-08-02 Glaxo Group Ltd Therapeutic compound for treating inflammation and allergy
BR9709650A (en) * 1996-06-04 1999-08-10 Procter & Gamble Nasal aerosol containing an intransal steroid and an antihistamine
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
US20030032632A1 (en) * 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033000A1 (en) * 2001-10-12 2003-04-24 Glaxo Group Limited Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma

Also Published As

Publication number Publication date
WO2002019995A3 (en) 2002-08-22
AU2001284287A1 (en) 2002-03-22
GB0021927D0 (en) 2000-10-25

Similar Documents

Publication Publication Date Title
US20240041846A1 (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US20030113269A1 (en) Medical combinations comprising tiotropium and fluticasone proprionate
US20030119859A1 (en) Medical combinations comprising tiotropium and rofleponide
WO2001078745A1 (en) Medical combinations comprising formoterol and fluticasone proprionate
WO2003024433A2 (en) Compositions for treatment of common cold, comprising ipratropium and xylometazoline
EP1274435A1 (en) Medical combinations comprising formoterol and budesonide
AU2002334126B2 (en) Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
EP1274440A1 (en) Medical combinations comprising tiotropium and mometasone
AU2002334126A1 (en) Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
US20040009963A1 (en) Use of salmeterol and fluticasone propionate combination
AU2008259864C1 (en) Methods and compositions for administration of Oxybutynin
US8415390B2 (en) Methods and compositions for administration of oxybutynin
US20030114537A1 (en) Medical combinations comprising mometasone and salmeterol
WO2001078744A1 (en) Medical combinations comprising formoterol and mometasone
WO2001078742A1 (en) Medical combination comprising salmeterol and budesonide
WO2002019995A2 (en) Pharmaceutical combination containing salmeterol and fluticasone
EP1274436A1 (en) Medical compositions comprising (r,r)-formoterol und rofleponide
US20030096874A1 (en) Respiratory compositions
WO2014105446A1 (en) Methods and compositions for administration of oxybutynin
KR20050094810A (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
US20040019025A1 (en) Medical compositions comprising (r,r)-formoterol and rofleponide
AU2002329578B2 (en) Compositions for treatment of common cold
AU2002329578A1 (en) Compositions for treatment of common cold
HK1092064A (en) Compositions comprising ipatropium and xylometazoline for treatment of the common cold

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP